Oric Pharmaceuticals (ORIC) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tyra Biosciences (TYRA) has outperformed Oric Pharmaceuticals (ORIC) over the past year, gaining 52.5% versus a loss of 14.9%. Over five years, TYRA leads with a +24.8% price change compared with -26.0% for ORIC. Tyra Biosciences is the larger company by market cap ($1.37 billion vs $1.25 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORIC | TYRA |
|---|---|---|
| Share price | $12.03 | $19.97 |
| Market cap | $1.25B | $1.37B |
| 1-day change | +0.17% | -2.06% |
| YTD return | +46.82% | -22.44% |
| 1-year return | -14.94% | +52.51% |
| 5-year return | -26.00% | +24.79% |
| EPS (TTM) | $-1.32 | $-2.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.68 | $40.65 |
| 52-week low | $7.23 | $13.29 |
| Distance from 52-week high | -18.05% | -50.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +78.14% | +137.61% |
| Average volume | 1.45M | 857.13K |
| Shares outstanding | 103.65M | 68.76M |
| Employees | 111 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TYRA has outperformed ORIC by 67.4 percentage points over the past year.
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
ORIC vs TYRA FAQ
Which is bigger, Oric Pharmaceuticals or Tyra Biosciences?
Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.37B compared with $1.25B for Oric Pharmaceuticals (ORIC).
Which stock has performed better over the past year, ORIC or TYRA?
TYRA returned +52.51% over the past 12 months, compared with -14.94% for ORIC (price return, excluding dividends). Past performance does not predict future results.
Are Oric Pharmaceuticals and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.